NeuroSens will be providing daily coverage of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 annual meeting, to be held September 24-26 in Barcelona, Spain. Read More
Latest News
Baseline sNfL prognostic of disease activity in CIS
August 21, 2025Higher baseline levels of serum neurofilament-light chain (sNfL) are prognostic of disease activity in patients with clinically isolated syndrome, according to a retrospective analysis of 181 individuals presenting with CIS at two MS centres in Spain during the period 2004-2022 (Comabella et al. Neurol Neuroimmunol Neuroinflamm 2025;12:e200370). Read More
CLINICAL CASES IN MS: A PATIENT CONSIDERING TREATMENT DISCONTINUATION
August 19, 2025P.B. is a 57-year-old woman with a 24-year history of relapsing-remitting multiple sclerosis. She was treated with an injectable from 2002-2012. Her last relapse was in 2009. She was transitioned to fingolimod in 2012 because of ongoing MRI changes and increasing tolerability issues. Read More
CLINICAL CASES IN MS: A PATIENT WITH MRI LESIONS CONSISTENT WITH MS
July 22, 2025Click here to watch Dr. Courtney Casserly discuss the case and the responses to the survey.
J.M. is a 28-year-old woman who had an MRI of the brain ordered by her nurse practitioner because of worsening of longstanding migraine headaches. The MRI demonstrated several lesions consistent with MS including two small enhancing lesions and multiple nonspecific supratentorial T2 hyperintensities. Your review of the history reveals nothing suggestive of a demyelinating episode. There is no family history of MS. She has an older brother with ulcerative colitis. The neurological examination was completely normal with borderline questionable pallor of the left optic disc.